Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection

被引:40
作者
Simon, V
Padte, N
Murray, D
Vanderhoeven, J
Wrin, T
Parkin, N
Di Mascio, M
Markowitz, M
机构
[1] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[2] ViroLog Inc, San Francisco, CA USA
[3] Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA
关键词
D O I
10.1128/JVI.77.14.7736-7745.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
It is believed that replication capacity is an important determinant of human immunodeficiency virus type 1 (HIV-1) pathogenicity and transmissibility. To explore this, we conducted a comprehensive analysis of the replication properties of nine drug-resistant and nine drug-susceptible viral isolates derived from patients with primary HIV-1 infection. Viral isolates were tested for single-cycle infectivity in the GHOST cell line. The infectivity of isolates carrying resistance-associated mutations was significantly higher than that of drug-susceptible isolates. Additionally, the growth kinetics of these isolates were determined in CD4(+) T lymphocytes. Drug-resistant isolates replicated as well as drug-susceptible viruses. Insertion of the resistance-conferring regions into an NL4-3-based molecular background resulted in chimeras that displayed a modest but significant reduction in replication capacity compared to the drug-susceptible chimeric viruses. Of note, two multidrug-resistant isolates and one protease inhibitor-resistant isolate displayed higher rates of infectivity and growth kinetics than the other drug-resistant or drug-susceptible isolates. These distinct replicative features, however, were not seen in the corresponding chimeras, indicating that changes within the C-terminal region of Gag as well as within the protease and reverse transcriptase genes contribute to but are not sufficient for the level of compensatory adaptation observed. These findings suggest that some drug-resistant viruses isolated during primary infection possess unique adaptive changes that allow for both high viral replication capacity and resistance to one or more classes of antiretroviral drugs. Further studies are needed to elucidate the precise regions that are essential for these characteristics.
引用
收藏
页码:7736 / 7745
页数:10
相关论文
共 48 条
[1]   Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture [J].
Archer, RH ;
Dykes, C ;
Gerondelis, P ;
Lloyd, A ;
Fay, P ;
Reichman, RC ;
Bambara, RA ;
Demeter, LM .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8390-8401
[2]   Deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase [J].
Back, NKT ;
Berkhout, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2484-2491
[3]   Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1 [J].
Bleiber, G ;
Munoz, M ;
Ciuffi, A ;
Meylan, P ;
Telenti, A .
JOURNAL OF VIROLOGY, 2001, 75 (07) :3291-3300
[4]   Predicting the unpredictable: Transmission of drug-resistant HIV [J].
Blower, SM ;
Aschenbach, AN ;
Gershengorn, HB ;
Kahn, JO .
NATURE MEDICINE, 2001, 7 (09) :1016-1020
[5]   HIV-1 drug resistance in newly infected individuals [J].
Boden, D ;
Hurley, A ;
Zhang, LQ ;
Cao, YZ ;
Guo, Y ;
Jones, E ;
Tsay, J ;
Ip, J ;
Farthing, C ;
Limoli, K ;
Parkin, N ;
Markowitz, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141
[6]   Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug [J].
Borman, AM ;
Paulous, S ;
Clavel, F .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :419-426
[7]   Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].
Brenner, BG ;
Routy, JP ;
Petrella, M ;
Moisi, D ;
Oliveira, M ;
Detorio, M ;
Spira, B ;
Essabag, V ;
Conway, B ;
Lalonde, R ;
Sekaly, RP ;
Wainberg, MA .
JOURNAL OF VIROLOGY, 2002, 76 (04) :1753-1761
[8]   Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication [J].
Caliendo, AM ;
Savara, A ;
An, D ;
DeVore, K ;
Kaplan, JC ;
DAquila, RT .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2146-2153
[9]   Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir [J].
Côté, HCF ;
Brumme, ZL ;
Harrigan, PR .
JOURNAL OF VIROLOGY, 2001, 75 (02) :589-594
[10]   Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease [J].
Dauber, DS ;
Ziermann, R ;
Parkin, N ;
Maly, DJ ;
Mahrus, S ;
Harris, JL ;
Ellman, JA ;
Petropoulos, C ;
Craik, CS .
JOURNAL OF VIROLOGY, 2002, 76 (03) :1359-1368